Integrating targeted agents into planning strategies for the treatment of metastatic colorectal cancer Journal Article

  


Author: Ilson, D. H.
Article Title: Integrating targeted agents into planning strategies for the treatment of metastatic colorectal cancer
Abstract: The introduction of the targeted agents bevacizumab and cetuximab in 2004 has had a significant impact on the management of metastatic colorectal cancer (mCRC). These targeted agents allow clinicians to offer more treatment options and lines of therapy, as well as to extend the duration of therapy. Moreover, the toxicities of the targeted agents generally do not overlap with those of the cytotoxic agents. Bevacizumab is recommended for use in all five first-line regimens for patients with mCRC who can tolerate intensive therapy; cetuximab is recommended for use in later-line therapies. Evidence from key clinical trials shows bevacizumab can achieve a significant survival benefit, and cetuximab has clear single-agent activity and induces responses in a subset of patients; it appears to have a special utility in resensitizing patients to irinotecan. The integration of bevacizumab and cetuximab into first-, second-, and later-line therapies continues to be explored in ongoing trials. Other novel agents that target the epidermal growth factor receptor, the vascular endothelial growth factor receptor, and other growth factor receptor pathways are also well along in clinical development. © 2006 Elsevier Inc. All rights reserved.
Keywords: clinical trial; review; bevacizumab; cytotoxic agent; fluorouracil; sunitinib; drug efficacy; hypertension; treatment duration; treatment planning; capecitabine; colorectal cancer; vasculotropin receptor; metastasis; epidermal growth factor receptor; combination chemotherapy; cetuximab; irinotecan; panitumumab; drug receptor binding; hypomagnesemia; hypokalemia; drug mechanism; thromboembolism; folinic acid; vatalanib; antihypertensive agent; drug half life; oxaliplatin; dry skin; digestive system perforation; fluoropyrimidine; artery thrombosis; hypocalcemia; skin fissure; growth factor receptor
Journal Title: Community Oncology
Volume: 3
Issue: 6 Suppl.2
ISSN: 1548-5315
Publisher: Elsevier Inc.  
Date Published: 2006-06-01
Start Page: 12
End Page: 17
Language: English
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-33746928444&partnerID=40&md5=b7f5c9d0a2a05fd190726a1317d69a9a
Notes: --- - "Export Date: 4 June 2012" - "Source: Scopus"